CK-0804

N/A

Report date: 2024/11/15 09:40:07

Base Information

Drug NameCK-0804
Drug Alias NameCK-0804CK-08041
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsC-X-C motif chemokine ligand 12
Therapy Area/IndicationsPrimary Myelofibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellenkos Inc
China Registration ClassN/A

Develop Information

Active CompaniesCellenkos IncIncyte Corp
Inactive CompaniesN/A
Active IndicationsPrimary Myelofibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A